PT 2385

Drug Profile

PT 2385

Alternative Names: HIF 2a; PT2385

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer National Cancer Institute (USA); Peloton Therapeutics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Indenes; Small molecules
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma; Renal cell carcinoma

Most Recent Events

  • 28 Mar 2018 Chemical structure information added
  • 06 Mar 2018 Phase-I development in Renal-cell-carcinoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in ongoing in USA (NCT02293980)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top